Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
复制标题
较低的血清成纤维细胞活化蛋白有望排除糖尿病和肥胖症中非酒精性脂肪肝引起的临床显着肝纤维化。
DOI：
10.1016/j.diabres.2015.02.024
复制
发表时间：
2015
影响因子：
5.1
通讯作者：
Gorrell,MD
中科院分区：
文献类型：
--
作者：
Williams,KH;VieradeRibeiro,AJ;Prakoso,E;Veillard,AS;Shackel,NA;Bu,Y;Brooks,B;Cavanagh,E;Raleigh,J;McLennan,SV;McCaughan,GW;Bachovchin,WW;Keane,FM;Zekry,A;Twigg,SM;Gorrell,MD
非酒精性脂肪性肝病（NAFLD）在糖尿病和肥胖症中很常见，但很少有临床显著的肝纤维化。改进的风险评估是必要的，因为常用的临床风险算法，NAFLD纤维化评分（NFS），往往是不确定的。目的为了确定循环成纤维细胞活化蛋白（cFAP），这是肝硬化升高，是否有价值，排除显着的纤维化，方法对106例2型糖尿病患者进行瞬时弹性成像，结果在队列1中，cFAP（每SD）与中值肝硬度（LSM）≥10.3 kPa独立相关，OR为2.0（95%CI 1.2-3.4），p= 0.006。与最高FAP三分位数相比，最低FAP三分位数中LSM ≥ 10.3 kPa的OR为0.12（95% CI 0.03-0.61）（p= 0.010）。FAP水平低于730 pmol AMC/min/mL，LSM ≥ 10.3 kPa的NPV为95%，64例受试者中有41%从NFS“不确定风险”重新分类为“低风险”。在队列2中，cFAP（每SD），与1.7倍（95%CI 1.1-2.8）显著纤维化（F≥ 2）的几率增加相关，p= 0.021，低cFAP将73例受试者中的49%从“不确定风险”重新分类为“低风险”。
Non-alcoholic fatty liver disease (NAFLD) is common in diabetes and obesity but few have clinically significant liver fibrosis. Improved risk-assessment is needed as the commonly used clinical-risk algorithm, the NAFLD fibrosis score (NFS), is often inconclusive.AimsTo determine whether circulating fibroblast activation protein (cFAP), which is elevated in cirrhosis, has value in excluding significant fibrosis, particularly combined with NFS.MethodscFAP was measured in 106 with type 2 diabetes who had transient elastography (Cohort 1) and 146 with morbid obesity who had liver biopsy (Cohort 2).ResultsIn Cohort 1, cFAP (per SD) independently associated with median liver stiffness (LSM) ≥10.3 kPa with OR of 2.0 (95% CI 1.2–3.4),p= 0.006. There was 0.12 OR (95% CI 0.03–0.61) of LSM ≥ 10.3 kPa for those in the lowest compared with the highest FAP tertile (p= 0.010). FAP levels below 730 pmol AMC/min/mL had 95% NPV for LSM ≥ 10.3 kPa and reclassified 41% of 64 subjects from NFS ‘indeterminate-risk’ to ‘low-risk’. In Cohort 2, cFAP (per SD), associated with 1.7 fold (95% CI 1.1–2.8) increased odds of significant fibrosis (F≥ 2),p= 0.021, and low cFAP reclassified 49% of 73 subjects from ‘indeterminate-risk’ to ‘low-risk’.ConclusionsLower cFAP, when combined with NFS, may have clinical utility in excluding significant fibrosis in diabetes and obesity.
登录
查看更多内容
人成纤维细胞激活蛋白的一种罕见变异，与内质网应激、酶功能丧失和细胞表面定位丧失相关。
DOI：
--
发表时间：
2014
期刊：
Biochimica et Biophysica Acta
影响因子：
--
作者：
B. Osborne;Tsun‐Wen Yao;X. M. Wang;Yiqian Chen;L. D. Kotan;N. A. Nadvi;M. Herdem;G. McCaughan;J. Allen;Denise M. T. Yu;A. Topaloğlu;M. Gorrell
通讯作者：
M. Gorrell
循环二肽基肽酶-4 活性与 2 型糖尿病和肥胖的非酒精性脂肪肝中肝细胞凋亡和纤维化的测量相关：一项双队列横断面研究
影响因子：
4.5
作者：
Kathryn H. Williams;Ana Júlia Vieira de Ribeiro;E. Prakoso;Anne‐Sophie Veillard;N. Shackel;B. Brooks;Y. Bu;E. Cavanagh;Jim Raleigh;S. Mclennan;G. McCaughan;F. Keane;A. Zekry;M. Gorrell;S. Twigg
通讯作者：
S. Twigg
第 5 章：靶向二肽基肽酶 4 (DPP-4) 和成纤维细胞激活蛋白 (FAP) 治疗糖尿病和癌症
DOI：
--
发表时间：
2011
期刊：
影响因子：
--
作者：
F. Keane;S. Chowdhury;Tsun‐Wen Yao;N. A. Nadvi;Margaret G. Gall;Yiqian Chen;B. Osborne;A. J. Ribeiro;W. B. Church;G. McCaughan;M. Gorrell;Denise M. T. Yu
通讯作者：
Denise M. T. Yu
蛋白酶作为药物靶点
DOI：
--
发表时间：
2012
期刊：
影响因子：
--
作者：
B. Dunn
通讯作者：
B. Dunn
影响因子：
4.6
作者：
Sahai-Hernandez, Pankaj;Nystul, Todd G.
通讯作者：
Nystul, Todd G.